ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.54
0.00%
US Tech 100
19,168.76
-0.20%
S&P 500
5,464.62
-0.16%
US Dollar vs CAD
1.36815
-0.15%
Bitcoin
61,139.96
-3.20%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Rocket Pharmaceuticals Inc (RCKT) Share Price

Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc (RCKT)

NASDAQ
22.48
1.63
(7.82%)
Closed June 21 3:00PM
Delayed by 15 minutes
22.48
0.00
( 0.00% )
Pre Market: 3:00AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
22.48
Bid
21.00
Ask
22.70
Volume
2
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
5.447M
Previous Close
22.48
Open
-
Last Trade
1
@
22.48
Last Trade Time
04:36:29
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
90,782,211
Dividend Yield
-
PE Ratio
-0.02
Earnings Per Share (EPS)
-2.71
Revenue
-
Net Profit
-245.6M

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesio... Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.rocketpharma.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Rocket Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RCKT. The last closing price for Rocket Pharmaceuticals was US$22.48. Over the last year, Rocket Pharmaceuticals shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Rocket Pharmaceuticals currently has 90,782,211 shares outstanding. The market capitalization of Rocket Pharmaceuticals is US$5.45 million. Rocket Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.02.

RCKT Latest News

More News

Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need...

May 29 2024
Business Wire

Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Long-term KRESLADITM follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety...

May 10 2024
Business Wire

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio...

May 06 2024
Business Wire

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Positive, previously disclosed results from the global Phase 1/2 trial demonstrated genetic and phenotypic correction combined with hematologic stabilization extending out to 42 months after...

April 02 2024
Business Wire

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planning, commercial finance, and capital allocation Additional key...

March 26 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

March 04 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 04 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

February 29 2024
Edgar (US Regulatory)
Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0

RCKT Discussion

View Posts
Monksdream Monksdream 6 months ago
RCKT new 52 week high
👍️0
make it happen make it happen 9 months ago
How's it up 38% @ $21.00 PPS when diluting $175,000,000 million @ $16.00??
👍️0
trkyhntr trkyhntr 4 years ago
I have been away at hunting camp for a few weeks, and when I got back I was pleasantly surprised. This puppy has doubled! Any thoughts as to how much more upside there is?
👍️0
ClayTrader ClayTrader 4 years ago
* * $RCKT Video Chart 12-09-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Glider549 Glider549 4 years ago
Check out Seeking Alpha, January 27, article.
Lots of insider buying and Fast Track status.
👍️0
RUSTYJ RUSTYJ 5 years ago
How you figure a lot power , Gravity takes it down
👍️0
investor86 investor86 6 years ago
This got a lot of power!!
👍️0
trkyhntr trkyhntr 6 years ago
This is a new board for this stock. Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.
👍️0

Your Recent History

NASDAQ
RCKT
Rocket Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved